CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway

CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway

CK2α/CSNK2A1 is involved in cancer progression by phosphorylating various signaling molecules. Considering the role of CSNK2A1 in cancer progression and the phosphorylation of SIRT6 and the role of SIRT6 in chemoresistance through the DNA damage repair pathway, CSNK2A1 and SIRT6 might be involved in...

Full description

Bibliographic Details
Main Authors:	Usama Khamis Hussein, Asmaa Gamal Ahmed, Yiping Song, Kyoung Min Kim, Young Jae Moon, Ae-Ri Ahn, Ho Sung Park, Su Jin Ahn, See-Hyoung Park, Jung Ryul Kim, Kyu Yun Jang
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Cells
Subjects:	osteosarcoma CSNK2A1 SIRT6 doxorubicin DNA damage prognosis
Online Access:	https://www.mdpi.com/2073-4409/10/7/1770

Similar Items

In Skeletal Muscle Fibers, Protein Kinase Subunit CSNK2A1/CK2α Is Required for Proper Muscle Homeostasis and Structure and Function of Neuromuscular Junctions
by: Mira Merholz, et al.
Published: (2022-12-01)

IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients
by: Maryam Karamikheirabad, et al.
Published: (2024-11-01)

Loss of Protein Kinase Csnk2b/CK2β at Neuromuscular Junctions Affects Morphology and Dynamics of Aggregated Nicotinic Acetylcholine Receptors, Neuromuscular Transmission, and Synaptic Gene Expression
by: Nane Eiber, et al.
Published: (2019-08-01)

Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2
by: Jie Wang(a), et al.
Published: (2022-06-01)

RETREG3/FAM134C phosphorylation by CSNK2 regulates reticulophagy during starvation
by: Giorgia Di Lorenzo, et al.
Published: (2022-12-01)

Unveiling the role of melatonin‐related gene CSNK1D in osteoclastogenesis and its implications for osteoporosis treatment
by: Jiewen Zhang, et al.
Published: (2025-02-01)

CSNK2A2 promotes hepatocellular carcinoma progression through activation of NF-κB pathway
by: Shuang Yang, et al.
Published: (2023-09-01)

Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2
by: Satoru Torii, et al.
Published: (2023-08-01)

CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway
by: Jiang C, et al.
Published: (2019-12-01)

CSNK2A1‐mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer
by: Zhan Shi, et al.
Published: (2021-08-01)

Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target
by: Liang Zhang, et al.
Published: (2024-08-01)

Melatonin mitigates doxorubicin induced chemo brain in a rat model in a NRF2/p53–SIRT1 dependent pathway
by: Neven A. Ebrahim, et al.
Published: (2024-10-01)

De Novo CSNK2B Mutations in Five Cases of Poirier–Bienvenu Neurodevelopmental Syndrome
by: Qi Yang, et al.
Published: (2022-03-01)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
by: Hadeel Halalsheh, et al.
Published: (2023-07-01)

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling
by: Kezheng Peng, et al.
Published: (2023-06-01)

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

Melatonin Restores Autophagic Flux by Activating the Sirt3/TFEB Signaling Pathway to Attenuate Doxorubicin-Induced Cardiomyopathy
by: Yanyan Ma, et al.
Published: (2023-09-01)

Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial‐mesenchymal transition and modulating SIRT1/β‐catenin signaling pathway in breast cancer
by: Xiaoxia Jin, et al.
Published: (2019-03-01)

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury
by: Qingling Zhang, et al.
Published: (2023-08-01)

Splicing Interruption by Intron Variants in CSNK2B Causes Poirier–Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype–Phenotype Correlations
by: Wen Zhang, et al.
Published: (2022-06-01)

Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics
by: Laszlo Gyenis, et al.
Published: (2022-06-01)

CSNK1E is involved in TGF-β1 induced epithelial mesenchymal transformationas and related to melanoma immune heterogeneity
by: Wangbing Hong, et al.
Published: (2025-01-01)

Synthesis of 5-Benzylamino and 5-Alkylamino-Substituted Pyrimido[4,5-c]quinoline Derivatives as CSNK2A Inhibitors with Antiviral Activity
by: Kesatebrhan Haile Asressu, et al.
Published: (2024-02-01)

Circadian gene CSNK1D promoted the progression of hepatocellular carcinoma by activating Wnt/β-catenin pathway via stabilizing Dishevelled Segment Polarity Protein 3
by: Mengqi Zhu, et al.
Published: (2022-12-01)

Yellow Wine Polyphenolic Compounds Regulate SIRT3 Expression to Alleviate Doxorubicin-induced Myocardial Injury
by: Shimin SUN, Zhenzhu SUN, Jufang CHI, Hangyuan GUO
Published: (2022-06-01)

Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade
by: Fatemah A. Alherz, et al.
Published: (2024-08-01)

Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex
by: Li Gu, et al.
Published: (2023-06-01)

TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity
by: Chao-Yung Wang, et al.
Published: (2020-10-01)

PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients
by: Junyue Zhang, et al.
Published: (2024-08-01)

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2
by: Han Wee Ong, et al.
Published: (2024-09-01)

Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy
by: Daniela Chirio, et al.
Published: (2022-06-01)

CK2 Regulation: Perspectives in 2021
by: Scott E. Roffey, et al.
Published: (2021-09-01)

Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis
by: Wei H, et al.
Published: (2022-08-01)

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
by: Bin Zhang, et al.
Published: (2020-02-01)

Cariporide Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Inhibiting Oxidative Stress, Inflammation and Apoptosis Partly Through Regulation of Akt/GSK-3β and Sirt1 Signaling Pathway
by: Wenli Liao, et al.
Published: (2022-06-01)

Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma
by: Yang Liu, et al.
Published: (2024-08-01)

De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway
by: Maria Asif, et al.
Published: (2022-07-01)

A new approach to the development and assessment of doxorubicin-loaded nanoliposomes for the treatment of osteosarcoma in 2D and 3D cell culture systems
by: Mastaneh Parchami, et al.
Published: (2023-05-01)

Altered expression of Csnk1a1p in Autism Spectrum Disorder in Iranian population: case-control study
by: Zahra Rahmani, et al.
Published: (2024-11-01)

Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma
by: Lulin Wang, et al.
Published: (2020-07-01)